KLK3 and prostate cancer: Prostate-specific antigen (PSA) has been criticized for its low specificity for prostate cancer, which has led to the increased adoption of additional biomarkers, PSA density (PSAD), and multiparametric magnetic resonance imaging (mpMRI) to increase the localization, risk stratification, and diagnosis of prostate cancer.